Sarepta Therapeutics

View All

Duchenne-Muscular-Dystrophy-Pipeline-Insight
In Search for a Curative Treatment Option for Duchenne Muscular Dystrophy

Sarepta Therapeutics, a leading player focused in developing precision genetic medicines for rare diseases with more than 25 programs ongoing, has recently announced the submission of New Drug Application (NDA) to the US FDA for Casimersen (SRP-4045) for the treatment of Duchenne muscular dystrophy (DMD) with a gen...

Find More

pharma-news
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result

Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases The engineered exosome technology is believed to improve the delivery of delivering gene therapy, gene editing and RNA technologies for ne...

Find More

Duchenne Muscular Dystrophy Market | DMD Market
Is the cure for Duchenne Muscular Dystrophy in the pipeline?

The Duchenne Muscular Dystrophy Market Size (DMD Market) in the 7MM was found to be USD 266.06 Million in 2017, during the study period (2017-2030). A rare muscle disorder, Duchenne Muscular Dystrophy (DMD), approximately affects 1 in 3,500 male births globally. Moreover, Duchenne Muscular Dystrophy prevalence ...

Find More

pharma news
Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy

Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion.  Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive rights to it globally except in the US.  As per t...

Find More

Notizia

Anylam, Regeneron to broaden the scope of R&D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody approach is going to get infused with USD 800 million upfront. The joint deal will help in expanding R&am...

Find More

Kidney Cancer
Notizia

CRISPR treatment delivers benefits in mice The researchers from Duke University along with drugmaker Sarepta Therapeutics published a report stating that a single change in the genetic system of Duchenne muscular dystrophy (DMD) affected mice, using CRISPR gene editing tool resulted in increasing their life spa...

Find More

Therapeutics
PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch

PMV Pharma Raises $74M, Aiming to Hit Cancer’s Hard Target- P53 PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company raised a $74 million Series B round from Topspin Biotech Fun...

Find More

FDA Approves Sarepta’s Muscular Dystrophy Drug after Months of Debate

The Food and Drug Administration approved the recent controversial drug to treat Duchenne muscular Dystrophy, which is a rare disease that confines boys to wheelchairs and condemns them to an early death. The decision was made after months of debate between the Agency and Sarepta Therapeutics, regarding the evidence...

Find More